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A B S T R A C T
Background
Open angle glaucoma (OAG) is a primary, progressive optic neuropathy; the onset is without symptoms and progression occurs silently
until the advanced stages of the disease, when it affects central vision. The blindness caused by OAG is irreversible. It has often been
assumed to be a condition that fulfils the criteria for population screening, although this has not been supported by other in-depth
non-systematic reviews. The focus of this review was to examine the evidence for the effectiveness of screening for OAG.
Objectives
To determine the impact of screening for OAG compared with opportunistic case findings or current referral practices on the prevalence
of and the degree of optic nerve damage due to OAG in screened and unscreened populations.
Search methods
We included any randomised controlled trial (RCT) evaluating population-based screening programmes for OAGwith a minimum one
year follow up. We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and
Vision Group Trials Register) (The Cochrane Library, Issue 4, 2008), MEDLINE (January 1950 to January 2009), EMBASE (January
1980 to January 2009), the UK Clinical Trials Gateway (UKCTG) and ZETOC (January 1993 to January 2009). There were no
language or date restrictions in the search for trials. The electronic databases were last searched on 12 January 2009.
Selection criteria
We planned to include RCTs, including cluster RCTs.
Data collection and analysis
Two review authors independently assessed the study abstracts identified by the electronic searches. We did not find any trials that met
the inclusion criteria.
Main results
As no trials were identified, no formal analysis was performed.
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Authors’ conclusions
On the basis of current evidence, population-based screening for chronic OAG cannot be recommended, although much can be done
to improve awareness and encourage at risk individuals to seek testing. In wealthy countries with equitable access to high quality
eye care and health education, blindness from chronic OAG should become increasingly rare; much greater challenges face poor and
emerging economies and countries where there are substantial health and wealth inequalities. Effectiveness of screening for OAG can
be established only by high quality RCTs.
P L A I N L A N G U A G E S U M M A R Y
Screening to prevent damage to the optic nerve due to open angle glaucoma
Open angle glaucoma (OAG) is the commonest type of glaucoma in white European and African people and is the commonest cause
of irreversible blindness. Its onset is insidious and progression symptomless until the condition is far advanced and central vision is
lost. Because of this, OAG is assumed to be a condition which should be screened for, but good evidence to support this is lacking.
Risk factors for developing OAG include increasing age, raised pressure inside the eye and a history in the family. It is more common
in people with African origin, may come on at an early age and is more aggressive. The field of vision (side vision) is gradually lost but
changes in the appearance of the optic nerve (where it appears inside the back of the eye) usually occur first. Raised pressure inside the
eye may not be present and many with raised pressure do not have glaucoma. Tests for the disease are examination of the optic nerve,
measurement of eye pressure and visual field assessment. The challenge of screening is to find people with the disease at a stage when
the diagnosis is not in doubt and at risk of going blind if left untreated.
The aim of this review was to determine the impact of screening on the prevalence and severity of optic nerve damage due to OAG.
We searched for randomised controlled trials (RCTs) of screening versus no screening for OAG because effectiveness of screening as
a means of preventing the ill effects of a disease in a population can only be demonstrated by RCTs. We identified 1360 reports of
studies but none were RCTs of screening. Therefore, there is insufficient evidence to recommend population based screening for OAG.
However much can be done to improve awareness of the condition and encourage those at higher risk to seek testing. In wealthy
countries where there is access to high quality eye care and good health education, blindness from OAG should become increasingly
rare. Much greater challenges face poor and emerging economies and countries where there is not equal access to good healthcare. The
potential effectiveness of screening for OAG in preventing optic nerve damage and ultimately preventing blindness should be tested
by high quality RCTs of screening.
B A C K G R O U N D
Introduction
Open angle glaucoma (OAG) is a primary, progressive optic neu-
ropathy, the commonest of a spectrum of diseases grouped under
the broad heading of glaucoma in Caucasian and African popu-
lations. The onset of OAG is without symptoms and progression
occurs silently until the advanced stages of the disease, when it en-
croaches on central vision. The blindness caused by OAG is irre-
versible. Owing to this and to the insidious nature of the onset and
progression of the disease, it has often been assumed that OAG is
a condition that fulfils the criteria for population screening. How-
ever, a number of in-depth non-systematic reviews failed to come
to that conclusion (Eddy 1983; Spry 2002;Wormald 1995). Prob-
lems identified were the lack of a single suitable screening test, un-
certainty about the effectiveness of treatment and poor knowledge
of the natural history of OAG.
More recently, new evidence has emerged on the effectiveness of
treatment (Maier 2005; Rolim de Moura 2007; Vass 2007) and
a number of new screening devices have been developed. There
have also been reports of combinations of tests performing more
efficiently than a single test in detecting the disease (Crick 1994;
Crick 1995; Tuck 1993). The focus of this review was on the
effectiveness of screening for OAG and excludes narrow or closed
angle, congenital and secondary glaucomas.
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Epidemiology
Glaucoma is a common cause of blindness worldwide. Prevalence
varies in different ethnic groups, with African races estimated as
having a four to five times greater prevalence of OAG than eth-
nic Europeans or Asians (Buhrmann 2000; Hyman 2001; Leske
1994). This condition is thought to account for between 0.8% to
3% of blindness in Caucasians (Cedrone 1997; Dielemans 1994;
Tielsch 1991; Wensor 1998) and as much as 28% in races of
African origin (Hyman 2001).
Risk factors for developing OAG include increasing age, raised
intraocular pressure (IOP), a family history of the disease, myopia
and African ethnic origin (Leske 1994; Mitchell 1999; Sommer
1991; Wolfs 1998).
The average age at diagnosis has been estimated as 62 years in
non-white populations and 70 years in white populations (Leske
1983).
Presentation and diagnosis
The onset ofOAG is painless andwith insidious loss of visual func-
tion, most notably of the field of vision. Changes in optic nerve
head appearance are generally thought to precede abnormalities of
the visual field, although this is not always the case. Raised IOP is
commonly associated with OAG but is now known not to be as
specific an indicator for the disease as once thought. Open angle
glaucoma is characterised by an open anterior chamber drainage
angle and the absence of any other putative causative factors such
as pigment dispersion syndrome, a history of exposure to steroid
medication or pseudoexfoliation.
Optic nerve changes
The initial changes in the optic nerve head are vertical extension of
the central cup and notching of the neuroretinal rim, which may
be preceded by focal splinter haemorrhages in the neuroretinal rim
(termed ’disc haemorrhages’). Further thinning of the neuroreti-
nal rim occurs with progression - typically inferotemporally and
superotemporally, then extending to the nasal side. Pathological
appearances of the optic nerve head in glaucoma are said to be typ-
ical, though not specific, since these changes can also be observed
in persons with normal optic nerve function or non-progressive
pathology.
Visual field changes
The earliest abnormalities in visual field sensitivity occur in the
paracentral region or in the ’nasal step’ area about 25 to 30 degrees
from fixation with asymmetry in sensitivity across the horizontal
meridian on the nasal side. New areas of relative loss of sensitivity
occur in an arcuate fashion above or below the blind spot (Bjer-
rum’s area), which extend with time to the periphery as they be-
come more profound in depth. Eventually, a central island with a
temporal crescent of sensitivity remains.
Up until this point central acuity may remain unaffected and then
it may quite suddenly fail. Sadly, especially in poorer countries,
this may be when the sufferer first becomes aware of the condition.
Intraocular pressure changes
Raised intraocular pressure is a major risk factor for the devel-
opment of OAG. It was previously thought that raised IOP was
part of the disease definition but epidemiological studies that re-
vealed the presence of glaucoma without raised IOP, and raised
IOP without glaucoma, led to re-evaluation of the relationship
between the two. Nevertheless, there remains firm evidence of a
causal relationship (Bahrami 2006) and the majority of interven-
tions for glaucoma are aimed at reduction of IOP. Pressure above
21 mm Hg in adults is generally accepted as being significantly
raised; this is based on statistical observations of mean IOP, with
22 mmHg being greater than themean IOP by twice the standard
error of the mean.
Natural History
Open angle glaucoma nearly always affects both eyes but there is
often a degree of asymmetry with one eye having more advanced
disease than the other at presentation. In these situations, a rela-
tive afferent pupillary defect can be detected. The natural history
of OAG is not well described. Much attention is given to early
detection of the disease because late presentation is a risk factor
for blindness. However, we do not know what proportion of early
presenters are at risk of progressing to severe visual loss. It is prob-
able that rates of progression vary and that determinants of this
variance may include higher IOP but also vulnerability of the op-
tic nerve. Because of this, there is a growing interest in measuring
rates of progression in glaucoma so that appropriate treatment can
be implemented. For screening, many now realise that tests for
reliable detection of definite disease are more important than early
detection.
Diagnosis
Tests for glaucoma involve: assessment of structural changes at the
optic nerve head and the progression of these changes; functional
visual loss assessed by visual field testing; and the level of IOP. A
diagnosis of OAG is based principally on the presence of glauco-
matous optic neuropathy affecting the appearance of the optic disc
or retinal nerve fibre layer in the presence of a normal drainage
angle. Definitions of abnormality are derived from describing nor-
mal population distributions and require the combination of cor-
roborating diagnostic elements (Foster 2002). The availability of
normative data for different technologies and different popula-
tions is limited.
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Structural loss: the optic nerve is assessed clinically by ophthal-
moscopy or photography, or both. New techniques for assessment
of the structural changes of the optic nerve have emerged.
1. The confocal scanning laser ophthalmoscope, commercially
available as the Heidelberg Retinal Tomogram (HRT), produces a
topographical image of the optic disc and peripapillary retina. The
second-generation instrument, HRTII, is portable and may have
better acceptability as a screening test in a primary care setting
than the original HRT.
2. Scanning laser polarimetry (SLP) quantifies the thickness of the
nerve fibre layer. Scanning laser polarimetry is available commer-
cially (GDx) and has recently been modified to compensate for
the variable properties of the cornea (GDx VCC) with improved
performance characteristics.
3. Optical coherence tomography (OCT) and the retinal thickness
analyser (RTA) have been introduced recently as possible tools to
identify early glaucoma.
Functional loss: the accepted standard for measuring glaucoma-
tous visual field loss is standard automated perimetry (SAP). The
Humphrey visual field analyser is the most commonly used tech-
nology of SAP. Other tests of visual function purporting to detect
disease at an earlier stage than SAP include frequency doubling
perimetric techniques (FDT), short wave automated perimetry
(SWAP) andmotion perimetry.Other functional tests are available
to detect established but early visual field loss, for example ’ocu-
lokinetic’ perimetry (OKP), suprathreshold perimetry andmotion
detection perimetry.
Intraocular pressure (IOP): the most widely used and generally ac-
cepted method for measuring IOP is contact applanation tonom-
etry; where a prism is used to apply a force to the cornea to indent
and flatten its surface (Goldmann 1955). Contact tonometers in-
clude the Goldmann, the Perkins and the Tonopen. Non-contact
tonometers applanate the cornea with a puff of air (Shields 1980).
Inaccuracies in IOPmeasurement can be induced bymeasurement
technique and by variability of the central corneal thickness.
A systematic review of the diagnostic accuracy of screening tests
for OAG is currently underway and information on the progress
of this project can be found on the Health Technology Assessment
website (http://www.hta.nhsweb.nhs.uk/ProjectData/1_project_
record_published.asp?PjtId=1027&SearchText=). This review
which includes economic modelling should help define the most
appropriate screening test strategies and cut off criteria for onward
referral.
Screening for glaucoma
To the best of our knowledge there are no formal glaucoma screen-
ing programmes with defined ’at risk’ target populations and in-
terval screening in existence in any country. However, a number
of ad hoc strategies exist. In the USA, the American Academy of
Ophthalmologists recommend screening in healthy adults with no
risk factors at least once between the ages of 20 and 29 years, twice
between 30 and 39 years, every 2 to 4 years between 40 to 64 years
and every 1 to 2 years when aged 65 and older. However, funding
support varies from state to state and is often non-existent. The
International Glaucoma Association (IGA) have likewise made
recommendations on screening and in Britain, free sight tests are
offered to persons over 40 years of age if there is a history of an af-
fected first-degree relative. However, this does not constitute a for-
mal attempt to reach and test everyone at risk in a defined popula-
tion and is perhaps better termed opportunistic surveillance rather
than screening (Wormald 1995). Guidelines are provided by the
British College of Optometrists indicating which tests should be
done and when but these are not enforced. Uptake of sight testing
by the British population is variable and the less well educated and
more deprived communities are less likely to seek testing (Fraser
2001).
Ideally, guidelines for screening for OAG should be based on evi-
dence of effectiveness in studies designed so that the participants
in the screened and unscreened arms are essentially the same age
with the same baseline risk for the disease. To achieve this, ran-
domisation within birth year cohorts is essential. For example, in
a study of 200 general practices, everyone aged 40 to 45 years in
a randomly sampled 100 practices would be invited for glaucoma
screening. Five years later, everyone who was invited for initial
screening and everyone 45 to 50 years of age in the previously un-
screened 100 practices would be invited for screening. The study
might be powered on the assumption that the prevalence of glau-
coma causing visual impairment sufficient to disqualify fitness to
drive would be lower in the screened population since more cases
would have been detected at an earlier stage of the disease and
successfully treated.
Treatment options
In a systematic review of treatment effectiveness, IOP lowering
treatment was found to be effective for reducing glaucoma pro-
gression (Maier 2005). Other ongoing or completed Cochrane re-
views (Burr 2005; Rolim deMoura 2007; Sycha 2003; Vass 2007)
provide further details on the effectiveness of various treatment
options. The focus of this review was on evaluating the effective-
ness of screening.
Rationale for a systematic review
The challenge of screening for OAG is to detect the disease at a
stage where it is sufficiently present to be accurately identified in
those individuals who are at risk of going blind in their lifetime
if left untreated. Detecting very early disease may not necessarily
be the most effective and efficient way to screen if resources are
to be focused on those at risk of blindness. Attempting to detect
the condition in its very early stages is likely to generate more false
positive errors and identify numerous people whose sight is not
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threatened. Ultimately, the effectiveness of screening as a means of
preventing the adverse effects of a disease in a population can be
demonstrated only by randomised trials of screening where indi-
viduals or clusters of individuals are randomised to be screened, or
not, thereby testing the hypothesis that screened individuals will
have a lower risk of suffering the effects of the disease than the
unscreened individuals. The randomised controlled trial (RCT) is
the only study design that can deal with both length bias and lead
time bias (Warwick 2005), if the appropriate outcomes have been
selected. The rationale of this review was to systematically search
and review RCTs of screening for OAG.
O B J E C T I V E S
To determine the impact of screening for open angle glaucoma
(OAG) compared with opportunistic case finding and current re-
ferral practices on the prevalence and severity of optic nerve dam-
age due to OAG in screened and unscreened populations. This as-
sumes that successful detection and subsequent treatment of OAG
leads to a lower prevalence of advanced optic nerve damage in
screened versus unscreened populations.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) of screening versus no screen-
ing for open angle glaucoma (OAG) were eligible for inclusion.
We anticipated that eligible studies would take the form of cluster
RCTs. Relevant RCTs would be those that contrasted screening
with no screening. The reference strategy of no screening could
include case finding, that is opportunistic screening. We did not
include trials that compared different screening strategies.
We considered any method of randomisation, including those in
which individuals, locations or practices were randomised. Differ-
ences in study quality were taken into account in the analysis. Ide-
ally, trials would have analysed data on an intention-to-treat basis.
We planned to include other types of analysis and use an available
case-based analysis provided that all randomised participants were
accounted for.
Types of participants
We considered studies from any population and reported major
differences in the populations studied, such as age at screening
and race when analysing the results. We expected persons already
known to have glaucoma, already under the care of an eye specialist
or known to be visually impaired for other reasons not to have
been included in routine screening. Screening was likely to detect
other degenerative eye conditions and other forms of glaucoma
(including secondary open angle disease such as pseudoexfoliative
and pigment dispersion glaucoma) though these were not included
as the primary outcome of the review.
Types of interventions
Studies of any screeningmodality forOAGwere eligible.We noted
different screening techniques and considered any knowledge of
test sensitivity and specificity in the discussion of the results
Types of outcome measures
Primary outcomes
We considered any or all of the following three primary outcomes
for this review; measured at a minimum of one year postscreening.
1. Prevalence of any degree of characteristic visual field loss in
screened and non-screened populations as diagnosed by any au-
tomated or manual visual field assessment (excluding confronta-
tion). The proportion of persons with a predetermined severity of
field loss (attributable to glaucoma) were compared in the screened
and unscreened populations. The severity should correlate with
existing trials for the prevention of OAG, for example, the Euro-
pean Glaucoma Prevention Study (EGPS) or the Ocular Hyper-
tension Treatment Study (OHTS).
2. Prevalence of optic nerve damage in screened and non-screened
populations as diagnosed by any method of imaging. Differences
in the prevalence of a prespecified degree of structural optic nerve
damage was examined in screened and unscreened populations.
3. Prevalence of visual impairment in screened and non-screened
populations as defined by number of participants certified or reg-
istered according to national or regional (where the study was con-
ducted) standards:
i. blind;
ii. partially sighted;
iii. vision below standard for driving.
Secondary outcomes
Screeningmay lead tomore treatment and subsequently to a lower
mean intraocular pressure (IOP) in screened than unscreened pop-
ulations. Intraocular pressure is a surrogate outcome but, never-
theless, indirect evidence of the effectiveness of screening could
be derived from a reduction in the severity of this most well-es-
tablished and modifiable risk factor. Any differences in mean IOP
in screened and unscreened populations would be reported at a
minimum of one year postscreening.
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Adverse effects (severe, minor)
Severe: false negatives results in persons with glaucoma who pass
screening and go on to lose vision.
Minor: false positives results in persons without glaucoma who
fail screening and are referred for further investigation but who
do not undergo any treatment. Referral causes an excess burden
on health services and unnecessary inconvenience and anxiety for
individuals.
Quality of life measures
Various vision-specific quality of life measures are in use, for ex-
ample the Visual Function Questionnaire (VFQ) and the Na-
tional Eye Institute Visual Function Questionnaire (NEI VFQ-
25).Other glaucoma specificmeasures such as theGLQ15 (Nelson
2003) have been shown to correlate better with objective measures
of disease progression.
The impact of glaucoma on health status (utility valuation) can
be assessed using preference-based measures. These include time
trade off, standard gamble (using a gamble of death or blindness,
for example), the EQ5D (EuroQol 1990) and the Health Utili-
ties Index Mark111 (HUI3) (Horsmann 2003). Any measures of
quality of life or health status attributable to the screening or OAG
would be reported.
Economic data
We planned to report any economic data available on the costs
and cost-effectiveness of programme implementation, cost per case
identified or other costs relating to the screening programme. Eco-
nomic data are often the products of the aggregation of other data;
for example, total cost would be an aggregate of the costs of the
intervention plus the cost-consequences of that intervention, such
as the treatment of complications. The methods and reporting of
such aggregation can also be quality assessed.Where economic data
(costs, economic measures of effectiveness such as quality adjusted
life years, and cost-effectiveness) are reported additional quality
assessment is required.We intended to use theDrummond check-
list for the critical appraisal of economic evaluations (Drummond
1997).
Other outcomes
Weplanned to report any technical differences between the screen-
ing and control interventions, the quality of the intervention in-
cluding any quality control measures, rates of participation, con-
tamination and follow up in the screening and control arms.
Follow-up
A minimum follow up of one year postscreening was required for
study inclusion. Where follow up varied between included studies
this would be recorded and reported in the discussion.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL) (which contains the Cochrane Eyes and Vision
Group Trials Register) (The Cochrane Library, Issue 4, 2008),
MEDLINE (January 1950 to January 2009), EMBASE (January
1980 to January 2009), theUKClinical TrialsGateway (UKCTG)
and ZETOC (January 1993 to January 2009). There were no lan-
guage or date restrictions in the search for trials. The electronic
databases were last searched on 12 January 2009.
See: Appendices for details of search strategies for CENTRAL
(Appendix 1),MEDLINE (Appendix 2), EMBASE (Appendix 3),
UKCTG (Appendix 4) and ZETOC (Appendix 5).
Searching other resources
We carried out nomanual handsearching of journals or conference
proceedings for this review although, if possible, these will be
included in any updates. Regular contact with experts in the field
should allow discovery of any unpublished or ongoing trials.
Data collection and analysis
Assessment of search results
Two review authors (RW, SH) independently assessed all titles and
abstracts from the electronic searches.Wedidnot identify any trials
meeting the inclusion criteria for this review but in future updates
we will obtain full reports for any studies that appear to be eligible
and contact study authors if there is insufficient information in
the full report, in order to enable inclusion wherever possible. Any
disagreement between authors RWand SH regarding the inclusion
of studies will be resolved by discussion with the third review
author (JB). Details of excluded studies will be documented in the
appropriate section of the review.
Methods to be used in updates to the review
For updates of this review, we will include any trial reports that
become available in the future using the following methods.
Assessment of methodological quality
Each eligible studywill be independently assessed formethodolog-
ical quality by two authors (SH, RW). Each of the following pa-
rameters will be graded as either Yes (indicating adequate measures
were taken and there is therefore a low risk of bias), No (indicating
adequate measures were not taken and there is therefore a high
risk of bias), or Unclear, as outlined in Chapter 8 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2008a).
Additional information from study authors will be sought if any
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criteria are graded unclear. Any disagreements will be resolved by
discussion with the third author (JB).
The following potential areas of bias will be examined for quality.
1. Sequence generation
We will note methods used to generate the random sequence and
what method of randomisation was used. We will include studies
where communities were randomly selected for screening or no
screening and then compared with each other after a period of
follow up.
2. Allocation concealment
We will assess how adequately allocation was concealed until after
the intervention was assigned.
3. Masking (blinding)
Assessor masking will be graded according to whether it was
present or absent. We anticipate that assessors will be unaware of
the previous screening status of individuals when assessing out-
come.
Participants in the screened arm of any study included in this
review will be aware of their allocated intervention. Those not
screened may not be aware that they are in the control arm until
follow up.
4. Incomplete outcome data
Some loss to follow up will be inevitable, and in the design
mentioned above, this will only be quantifiable in the previously
screened population. Where this is greater than 20%, the validity
of the study will be questioned if there is no information on the
characteristics of those lost to follow up or on whether their loss
may have introduced bias in the outcome.
5. Selective reporting
We expect data to be analysed on an intention-to-treat basis as de-
fined in the Cochrane Handbook for Systematic Reviews of Interven-
tions (Higgins 2008b) or at least on an available case-based anal-
ysis where participants are analysed as randomised. Where data
are missing or unclear the authors will be contacted for further
information.
6. Other biases
Economic assessment
The Drummond checklist for the critical appraisal of economic
evaluations (Drummond 1997) asks a series of questions relating
to the quality of the economic component of the study for which
the answers are classed as: Yes, No or Cannot tell.
1. Was a well-defined question posed in an answerable form?
2. Was a comprehensive description of the competing alternatives
given (that is, can you tell who did what, to whom, where, and
how often)?
3. Was there evidence that the programme’s effectiveness had been
established?
4.Were all important and relevant costs and consequences for each
alternative identified?
5. Were costs and consequences measured accurately in appropri-
ate physical units?
6. Were costs valued credibly?
7. Were consequences valued credibly?
8. Were costs adjusted for differential timing?
9. Were consequences adjusted for differential timing?
10. Was an incremental analysis of costs and consequences of al-
ternatives performed?
11. Did the presentation and discussion of study results include
all issues of concern to users?
Studies that do not present a full economic evaluation (studies
that report only costs or economic measures of effects) will only
be assessed against those questions that are relevant.
Data collection
Two authors (SH, RW) will independently undertake the data
extraction for eligible studies using the relevant forms developed
by the Cochrane Eyes and Vision Group. The extracted data will
be compared for differences and discrepancies will be resolved by
discussion.
Data entry
Both authors involved in the data extraction will independently
enter the extracted data into RevMan using the double-entry fa-
cility to check for errors. If data are missing or unclear we will
attempt to contact the authors for more information.
Data synthesis
Comparisons will be made between screened and unscreened pop-
ulations; if appropriate, results from included trials will be com-
bined in ameta-analysis using a random-effects model unless there
are very few trials in which case a fixed-effect model will be used.
Odds ratios and risk differences will be used to assess the im-
pact of screening of the risk of severe optic nerve damage from
OAG. Mean difference will be used to compare intraocular pres-
sure (IOP) levels in screened and unscreened populations. If sig-
nificant heterogeneity exists no meta-analysis will be conducted
and we will present a narrative summary.
As it is anticipated that cluster randomisation may be used in the
included studies we will use the appropriate methods for dealing
with this as outlined in Chapter 16 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2008b).
Subgroup analysis
Where possible we will compare the effectiveness of different
screening strategies to no screening or current practice in the fol-
lowing subgroup analysis.
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• Screening by optic nerve imaging, visual field assessment or
IOP measurement alone compared with any combination of
these tests.
Assessment of heterogeneity
We will assess for heterogeneity initially by examining the char-
acteristics of the included studies and looking at the overlap in
confidence intervals of the forest plots. Testing for statistical het-
erogeneity will be observed with the chi-squared test provided in
RevMan. Additionally, we will use the I-squared statistic to quan-
tify inconsistency between studies.
Sensitivity analysis
We will conduct sensitivity analyses by repeating the analysis and
excluding studies of lower methodological quality, that is graded
B or C on any parameter, or if assessor masking was absent.
R E S U L T S
Description of studies
The electronic searches identified 1360 reports of studies but none
fulfilled the inclusion criteria for the review. An update search was
done in January 2009. After deduplication the search identified a
total of 846 references. TheTrials SearchCo-ordinator scanned the
search results and removed any references which were not relevant
to the scope of the review. Two authors independently reviewed
the remaining references. We reviewed the full text for one study
(Stoutenbeek 2008) and found it to be ineligible for inclusion.
Overall we did not find any reports of studies that were eligible
for inclusion.
Risk of bias in included studies
As no trials met the inclusion criteria, we assessed none for quality.
Effects of interventions
Since no randomised controlled trials were identified, we extracted
no data and performed no analyses.
D I S C U S S I O N
Themanagement of open angle glaucomahas changed over the last
20 years as evidence on the effectiveness of treatment has emerged.
Lack of this evidence acted as an impediment to the implementa-
tion of screening but despite improved clarity regarding treatment
effectiveness uncertainties persist regarding the natural history of
the disease.
Twomajor sources of bias that would otherwise distort the findings
of observational studies can be dealt with only by randomised
controlled trials of screening.
Lead time bias occurs when the condition is detected at an earlier
stage through screening, although no influence on ultimate out-
come is achieved as a result of that earlier detection. The survival
is apparently greater because the condition is known about for
longer but an otherwise similar unscreened individual goes blind
at the same rate but spends less time aware of the problem. In such
a circumstance, it is fair to conclude that screening has done harm.
Length bias occurs because interval screening is more likely to de-
tect slowly progressive and indolent disease than aggressive rapidly
progressing glaucoma. Apparently, screening has led to the iden-
tification of more people with early stage disease being identified
who are at much lower risk of blindness. This apparent benefit
might actually be harmful if the risk of the adverse effects of dis-
ease in these mild cases is very low and the number of persons
with aggressive blinding glaucoma remains the same and the blind-
ness rates are unchanged. This point was specifically addressed in
the Rotterdam study where incident cases identified in a cohort
study were compared to those routinely identified by visiting op-
tometrists (Stoutenbeek 2008).
This is why we specifically searched for RCTs of screening in this
review; the only study design that can adequately deal with these
two sources of bias. However, the organisation and conduct of
such studies is demanding and long term follow up is required on
large numbers of people if there is to be any likelihood of detecting
an effect. It is perhaps not surprising that no such trials have been
identified and the justification for such a study will depend on the
refinement of screening test strategies and economic modelling of
potential benefit and cost.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
On the basis of current evidence, population based screening for
open angle glaucoma (OAG) cannot be recommended. Much can
be done to improve awareness of the condition and encourage at
risk individuals to seek testing using optimised detection strate-
gies, although it may not yet be clear what these are. Good clinical
method remains vital for the correct diagnosis of the disease so that
a prognosis and a treatment plan appropriate to that individual’s
estimated lifetime risk of sight loss can be made. In wealthy coun-
tries with equitable access to high quality eye care and good health
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education, blindness from OAG should become increasingly rare.
Much greater challenges face poor and emerging economies and
countries where there are substantial health and wealth inequali-
ties.
Implications for research
The effectiveness of screening for OAG can be established only
by high quality randomised trials. A number of preliminary issues
need to be dealt with before such trials can be undertaken. A bet-
ter understanding of testing technologies is needed and a much
improved quality of research (using STARDT) in different pop-
ulations is required to delineate optimum screening strategies in
terms of individual tests and technologies, combinations of tests
and test frequency. Economic modelling using the best tests delin-
eated above will help to decide whether opportunity cost and cost
benefit are potentially justifiable before committing to the longer
term studies measuring health impact and sight years saved. Better
monitoring of health outcomes in large populations using registers
of blindness by cause can provide surveillance for the observation
of the impact of prevention strategies over time.
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Glaucoma, Open-Angle
#2 open near/2 angle near/2 glaucoma*
#3 MeSH descriptor Ocular Hypertension
#4 ocular near/2 hypertensi*
#5 MeSH descriptor Intraocular Pressure
#6 intraocular near/2 pressure*
#7 POAG or IOP or OHT
#8 ((increas* or elevat* or high*) near/3 (ocular or intra-ocular) near/3 (pressure))
#9 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8)
#10 MeSH descriptor Vision Screening
#11 MeSH descriptor Mass Screening
#12 MeSH descriptor Vision Disorders
#13 MeSH descriptor Vision Tests
#14 (test* or screen* or diagnos* or assess*) near/5 (vision or pressure* or hypertensi*)
#15 (#10 OR #11 OR #12 OR #13 OR #14)
Appendix 2. MEDLINE search strategy
1 randomized controlled trial.pt.
2 (randomized or randomised).ab,ti.
3 placebo.ab,ti.
4 dt.fs.
5 randomly.ab,ti.
6 trial.ab,ti.
7 groups.ab,ti.
8 or/1-7
9 exp animals/
10 exp humans/
11 9 not (9 and 10)
12 8 not 11
13 exp glaucoma/
14 exp glaucoma open angle/
15 (open adj2 angle adj2 glaucoma$).tw.
16 exp ocular hypertension/
17 (ocular adj2 hypertensi$).tw.
18 exp intraocular pressure/
19 (intraocular adj2 pressure$).tw.
20 (OAG or IOP or OHT).tw.
21 (((increas$ or elevat$ or high$) adj3 (ocular or intra-ocular)) and pressure).tw.
22 exp cornea/
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23 cornea$ thick$.tw.
24 or/13-23
25 exp vision screening/
26 exp mass screening/
27 exp vision disorders/
28 exp vision tests/
29 screen$.tw.
30 or/25-29
31 24 and 30
32 12 and 31
31 24 and 30
32 12 and 31
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville et al (Glanville 2006).
Appendix 3. EMBASE search strategy
1 exp randomized controlled trial/
2 exp randomization/
3 exp double blind procedure/
4 exp single blind procedure/
5 random$.tw.
6 or/1-5
7 (animal or animal experiment).sh.
8 human.sh.
9 7 and 8
10 7 not 9
11 6 not 10
12 exp clinical trial/
13 (clin$ adj3 trial$).tw.
14 ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15 exp placebo/
16 placebo$.tw.
17 random$.tw.
18 exp experimental design/
19 exp crossover procedure/
20 exp control group/
21 exp latin square design/
22 or/12-21
23 22 not 10
24 23 not 11
25 exp comparative study/
26 exp evaluation/
27 exp prospective study/
28 (control$ or prospectiv$ or volunteer$).tw.
29 or/25-28
30 29 not 10
31 30 not (11 or 23)
32 11 or 24 or 31
33 exp glaucoma/
34 exp open angle glaucoma/
35 (open adj2 angle adj2 glaucoma$).tw.
36 exp intraocular hypertension/
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37 (ocular adj2 hypertens$).tw.
38 exp intraocular pressure/
39 (intraocular adj2 pressure$).tw.
40 (POAG or IOP or OHT).tw.
41 (((increas$ or elevat$ or high$) adj3 (ocular or intra-ocular)) and pressure).tw.
42 exp cornea/
43 cornea$ thick$.tw.
44 or/34-41
45 exp vision test/
46 exp mass screening/
47 exp school health services/
48 exp child health care/
49 exp vision disorder/
50 screen$.tw.
51 or/45-50
52 44 and 51
53 32 and 52
Appendix 4. UK Clinical Trials Gateway (UKCTG) search strategy
glaucoma* and screen*
Appendix 5. ZETOC search strategy
glaucoma* AND screen* AND optic nerve
WH A T ’ S N E W
Last assessed as up-to-date: 11 January 2009.
Date Event Description
28 November 2008 New search has been performed Issue 2, 2009: updated searches yielded no new trials.
H I S T O R Y
Protocol first published: Issue 3, 2006
Review first published: Issue 4, 2006
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Date Event Description
16 October 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
Conceiving the review: RW, JB
Designing the review: RW, SH, JB
Coordinating the review: RW, SH
Designing search strategies: CEVG Trials Search Co-ordinator
Undertaking searches: CEVG Trials Search Co-ordinator
Screening search results: RW, SH
Organising retrieval of papers: RW, SH, CEVG Trials Search Co-ordinator
Screening retrieved papers against inclusion criteria: RW, SH
Appraising quality of papers: RW, SH
Extracting data from papers: RW, SH
Writing to authors of papers for additional information: RW, SH
Providing additional data about papers: RW, JB
Obtaining and screening data on unpublished studies: RW, SH
Entering data into RevMan: RW, SH
Analysis of data: RW, JB, SH
Providing a methodological perspective: RW, JB
Providing a clinical perspective: RW, JB
Providing a policy perspective: RW, JB
Writing the review: RW, SH
Securing funding for the review: JB
Performing previous work that was the foundation of the current study: JB
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D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• Cochrane Eyes and Vision Group, UK.
External sources
• NHS R & D Health Technology Assessment programme, UK.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Mass Screening; Glaucoma, Open-Angle [∗diagnosis]; Optic Nerve Diseases [etiology; ∗prevention & control]
MeSH check words
Humans
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